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Abstract
Introduction: Patients undergoing coronary revascularization often require inotropic support that has been
associated with an increased risk for death and morbidity. The purpose of this study was to evaluate the effect of
levosimendan versus control on survival after coronary revascularization.
Methods: A systemic review and meta-analysis of the literature was carried out on published randomized
controlled clinical trials that investigated the efficacy of levosimendan compared to other therapy in patients
having coronary revascularisaion. The databases searched were Pubmed, EMBASE, the Cochrane Registry of Clinical
Trials and the metaRegister of Controlled Trials. Studies that compared levosimendan to any other therapy for
coronary revascularisation in adult humans and reported at least one outcome of interest were considered for
inclusion. Both percutaneous coronary intervention and cardiac surgery were included. Data extraction was
performed independently by two reviewers using predefined criteria. Relevant outcomes included mortality, cardiac
index, cardiac enzymes, length of stay and post-procedural atrial fibrillation.
Results: The meta-analysis included 729 patients from 17 studies. Levosimendan was associated with a mortality
reduction after coronary revascularization, (19/386 in the levosimendan group vs 39/343 in the control arm) odds
ratio (OR) 0.40 (95% confidence interval (CI) 0.21 to 0.76, P for overall effect 0.005, P for heterogeneity = 0.33, I
2 =
12% with a total of 729 patients. Levosimendan also had a favourable effect on cardiac index (standardised mean
difference 1.63, 95% CI 1.43 to 1.83, P for overall effect < 0.00001), length of intensive care stay (random effects
model, mean difference - 26.18 hours 95% CI 46.20 to 6.16, P for heterogeneity < 0.00001, I
2 = 95%, P for overall
effect P = 0.01), reductions in the rate of atrial fibrillation (OR 0.54, 95% CI 0.36 to 0.82, P for effect = 0.004, P for
heterogeneity 0.84, I
2 = 0% for 465 patients) and troponin I levels group (mean difference -1.59, 95% CI 1.78 to
1.40, P for overall effect < 0.00001, P for heterogeneity < 0.00001, I
2 = 95%). Limitations of this analysis are
discussed.
Conclusions: Levosimendan is associated with a significant improvement in mortality after coronary
revascularization. There are also improvements in several secondary endpoints. A suitably powered randomised
controlled trial is required to confirm these findings and to address the unresolved questions about the timing and
dosing of levosimendan.
Introduction
Following coronary revascularisation, patients are still
vulnerable to a low cardiac output state and tissue hypo-
perfusion. Some patients may require bridging therapy
in order to realise the benefits of revascularisation.
There is substantial geographic variation, but it is
estimated that between 8 and 25% of patients under-
going coronary revascularisation require inotropic sup-
port for myocardial dysfunction [1-3]. This group of
patients carry a substantial burden of morbidity and
mortality [4]. Pharmacologic support is commonly lim-
ited to catecholaminesand phosphodiesterase III inhibi-
tors (PDEIs) with levosimendan gaining prominence [5].
There is a lack of suitably powered randomised control
trails to guide the choice of inotrope in this group of
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with increased post-operative myocardial oxygen con-
sumption and arrythmogenesis [6]. Additionally catecho-
lamines have also been associated with impaired
coronary vasodilatatory reserve [7].
Levosimendan sensitises myofilaments to calcium by
binding to the calcium saturated troponin C, increasing
their load-independent contraction [8]. The pleiotropic
effects of levosimendan include vasodilatation by open-
ing ATP-sensitive potassium channels (KATP) in vascular
smooth muscle as well as in mitochondrial KATP
channels.
Early clinical trials, though underpowered, have sug-
gested that levosimendan would be useful in the setting
of post coronary revascularisation myocardial dysfunc-
tion. More recently there have been several completed
clinical trials in this group of patients. The principal
objective of this study was to evaluate the association
between levosimendan, compared with conventional
therapy on mortality, in randomised control trialsin
patients having coronary revascularisation.
Materials and methods
Search strategy
The primary search for randomised clinical trials (RCTs)
was conducted using Pubmed, EMBASE and the
Cochrane Registry of Clinical Trials. The search term
used was ‘levosimendan’. The search was combined with
filters to identify RCTs in the Pubmed and EMBASE
database and is available as supplementary material (see
Additional file 1 for details). We also searched the
metaRegister of Controlled Trials using the term ‘levosi-
mendan’ [9]. No language restriction was placed but the
search was limited to adult human subjects. We used
backward snowballing by reviewing the bibliographies of
included RCTs and review articles to identify otherwise
unrecognised publications. The electronic database
search included publications from 1966 and was fina-
lised on 31 August 2010. The study did not require ethi-
cal approval.
Study selection
The authors reviewed all abstracts to identify potential
RCTs in a standardised manner. The inclusion criteria
were reports of RCTs that compared levosimendan to
any other therapy for coronary revascularisation in adult
humans and reported at least one outcome of interest.
Relevant outcomes included mortality, haemodynamic
parameters (for example, cardiac index), cardiac
enzymes, length of stay and post-procedural atrial fibril-
lation. If the abstract suggested that the study could
potentially meet the inclusion criteria, the full text arti-
cle was then retrieved and reviewed. Disagreements
between reviewers were resolved by consensus.
Data abstraction and study characteristics
All included studies were assessed for internal validity
and risk of bias according to the Cochrane Collabora-
tion methods. Each report was assessed for the adequacy
of allocation concealment, blinding, performance of an
intention to treat analysis and the extent of loss to fol-
low-up.
Data included baseline patient characteristics includ-
ing age and co-morbidity, baseline left ventricular ejec-
tion fraction, details of levosimendan dose and specifics
of comparator therapy, type of coronary revascularisa-
tion, haemodynamic and clinical outcome data. When
data was missing attempts were made to contact the
authors.
Data synthesis and analysis
Agreement on inclusion of studies was assessed using
the kappa statistic. Heterogeneity was measured using
the Cochrane Q test and quantified with the I
2statistic.
An I
2value of > 50% was considered at least moderate
heterogeneity.
Data from individual studies were collected to allow
calculation of odds ratio (OR). The primary analysis
was conducted by means of the Peto fixed effects
method when I
2 < 25% and with the random effects
model when I
2 > 25%. Weighted mean difference
(WMD) and 95% CI were calculated for continuous
variables (haemodynamics and troponin I). The poten-
tial for bias was assessed by visual inspection of funnel
plots. Sensitivity analyses were conducted by compar-
ing the fixed and random effects models as well as by
evaluating the risk of mortality in studies with a low
risk of bias only. The analysis was performed using sta-
tistical software SPSS 16 (SPSS Chicago, IL, USA) and
Revman 5.0 (available from the Cochrane Collabora-
tion Group). The study was performed in compliance
with the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) statement
[10,11].
Results
There were 680 reports identified by the search, 79 full
text articles retrieved for in depth review. We identified
17 eligible studies involving 729 patients that were
included in the final analysis. Figure 1 describes the flow
and reasons for exclusion. Agreement on study inclusion
was reached in 76 of the 79 cases (kappa = 0.92). The
characteristics of the included studies are described in
Table 1. An appraisal of study quality and risk of bias is
presented in Table 2. Overall studies were of variable
quality and many reports lacked relevant details to
assess selection, performance or reporting bias. A risk of
bias graph is included in the supplementary material
(see Additional file 2 for details).
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control intervention, levosimendan was associated with
a significant mortality reduction, (19/387 in the levosi-
mendan group vs 39/342 in the control arm) OR 0. 41
(95% CI 0.23 to 0.74, P for overall effect 0.005, P for
heterogeneity = 0.33, I
2 = 12% with a total of 729
patients) (Figure 2). A subgroup analysis comparing the
effect of levosimendan on mortality in elective versus
 
 
 
Literature search 
Databases : Pubmed, EMBASE, the 
Cochrane Library and Meta-registry of 
Controlled Clinical trials. (n=680) 
Additional records identified through 
review of references of initially 
retrieved articles (n=0) 
Search results combined n=680 
  601 articles excluded 
-animal studies (n=188) 
-paediatric studies(n=28) 
-reviews (n=150)  
- case reports(n=37) 
-letters(n=70) 
-editorials(n=23) 
-non-RCT clinical trials(n=38) 
-not relevant (n=67) 
Articles screened on the basis of title and 
abstract and 79 full text articles retrieved 
 
62 articles excluded 
-decompensated heart failure=43 
-duplicate publication=2 
-both groups received 
levosimendan=1 
-no relevant outcomes =2 
Included (n=17) 
 
Figure 1 Flow diagram of literature search and selection process of the studies.
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The elective revascularisation showed a statistically sig-
nificant mortality benefit compared with the emergency
revascularisation group (OR 0.36, 95% CI 0.18 to 0.72, P
for overall effect = 0.003, I
2 =0 %c o m p a r e dw i t hO R
0.61, 95% CI 0.19 to 1.89, P for overall effect = 0.39, I
2
= 69% respectively). All the emergency revascularisations
were PCI. The overall result was consistent when a ran-
dom effects model was used (OR 0.43 (95% CI 0.21 to
0.89)).
Levosimendan had a favourable effect on cardiac index
(standardised mean difference 1.63, 95% CI 1.43 to 1.83,
P for overall effect < 0.00001) although there was
significant heterogeneity (P < 0.000001 I
2 = 95%). A
sub-group analysis was undertaken to explore the het-
erogeneity. Subgroups were defined by the comparator
drug, that is, the placebo, dobutamine or phosphdiester-
ase inhibitors. The sub-group analysis did not show any
difference in treatment effect (Figure 3).
Post revascularisation, troponin I levels were signifi-
cantly higher in the control group compared with the
levosimendan group (mean difference -1.59, 95% CI 1.78
to 1.40, P for overall effect < 0.00001, P for heterogeneity
< 0.00001, I
2 = 95%) with 361 patients included (Figure 4).
There was a significantly lower rate of post-revascular-
isation new-onset atrial fibrillation in the levosimendan
Table 1 Description of the studies included in the meta-analysis
Source Year Patients Mean Age
(years ± SD)
Setting Time of
administration
Mean Baseline LVEF %
±S D
Control Follow-
up
Levosimendan Control Levosimendan Control
Al-Shawaf
et al. [35]
2006 30 60.5 ± 1 1 58 ± 10 Type 2 diabetes
with LCOS after
CABG.
Post
intervention
29 ± 6 31 ± 6 Milrinone Hospital
stay
Alvarez et al.
[36]
2005 30 71.5 ± 5.2 71.9 ±
5.2
Elective CABG with
LCOS
Post
intervention
35 ± 5 37 ± 4 Dobutamine Hospital
stay
Alvarez et al.
[37]
2006 50 71.2 ± 7.2 67.0 ±
8.0
Elective CABG with
LCOS
Post
intervention
35 ± 4 34 ± 5 Dobutamine Hospital
stay
Barisin et al.
[38]
2004 33 62.4 ± 7.1 57.9 ±
10.4
Elective OPCAB
with good LV
function
Pre-
intervention
62 ± 8 58 ± 10 Placebo Hospital
stay
De Hert et al.
[39]
2007 30 67 ± 11 69 ± 10 Elective CABG Intraoperatively 24 ± 6 27 ± 3 Milrinone Hospital
stay
De Hert et al.
[40]
2008 60 67.5 ± 9.5 69 ± 10 Elective CABG Inraoperatively 22 ± 5 25 ± 3 Milrinone Hospital
stay
De Luca et al.
[41]
2005 26 58.6 ± 8.7 57.1 ±
9.3
Acute MI
undergoing PCI
Post
intervention
28 ± 3 30 ± 3 Placebo Hospital
stay
Eriksson et al.
[42]
2009 60 64 ± 10 64 ± 10 Elective CABG with
LVEF<50%
Intraoperatively 36 ± 8 36 ± 8 Placebo Hospital
stay
Fuhrmann
et al. [33]
2008 32 68 ± 74 68 ±
8.1
Cardiogenic shock
after acute MI
Post
intervention
22 ± 9 27 ± 10 Enoximone Hospital
stay
Husedzinovic
et al. [43]
2005 24 61 ± 5.4 61 ±
5.3
Elective OPCAB
with normal LVEF
Pre-
intervention
56 ± 5 59 ± 2 placebo Hospital
stay
Jarvela et al.
[44]
2008 24 69 ± 11 67 ± 10 Elective AVR and
CABG
Intraoperatively 50 ± 4 65 ± 5 Placebo Hospital
stay
Levin et al.
[45]
2008 137 62.4 61.7 LCOS after elective
CABG
Post
intervention
37 ± 4 38 ± 5 Dobutamine Hospital
stay
Lilleberg
et al. [46]
1998 23 56.9 ± 7.9 59 ±
5.7
Elective low risk
CABG
Post
intervention
61 ± 9 58 ± 9 Placebo Hospital
stay
Samimi-Fard
et al. [47]
2008 22 65 ± 12 63 ± 11 Acute MI with
Cardiogenic shock
after PCI
Post
intervention
29 ± 2 30 ± 3 Dobutamine Two
years
Sonntag et al.
[48]
2004 24 60 60 PCI after acute MI Post
intervention
58 ± 3 62 ± 4 Placebo Hospital
stay
Tritapepe
et al. [49]
2006 24 66.5 ± 5.9 69.5 ±
5.6
Elective CABG Pre-
intervention
50 ± 7 52 ± 5 Placebo Hospital
stay
Tritapepe
et al.[ 1 ]
2009 106 66.5 ± 7.8 64. ± 8 Elective CABG Pre-
intervention
44 ± 10 42 ± 11 Placebo Hospital
stay
CABG, coronary artery bypass graft; LCOS, low cardiac output state; LVEF, left ventricular ejection fraction; MI, myocardial infarction; OPCAB, off pump coronary
artery bypass graft; PCI, primary coronary intervention.
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Page 4 of 10treated group (OR 0.54, 95% CI 0.36 to 0.82, P for effect
= 0.004, P for heterogeneity 0.84, I
2 = 0% for 465 patients
(Figure 5). There was also a significant difference in the
length of intensive care stay in favour of levosimendan
compared with control (random effects model, mean dif-
ference - 26.18 hours 95% CI 46.20 to 6.16, P for hetero-
geneity < 0.00001, I
2 = 95%, P for overall effect P =0 . 0 1 )
(Figure 6). The likelihood of small study bias robustness
was evaluated by inspection of the funnel plot (Figure 7).
Inspection of the funnel plot found no major evidence of
such bias and added to the validity and robustness of the
study. A sensitivity analysis that only included those
studies with a low risk of bias (Table 1) found an OR of
0.25 (95% CI 0.09 to 0.68). A further sensitivity analysis
to establish differential effects based on the comparator
w a sp e r f o r m e d .T h el a r g e s te f f e c ts i z ew a so b s e r v e di n
the levosimendan versus phosphodiesterase group (OR
0.23 (95% CI 0.08 to .65)). The levosimendan versus
dobutamine group showed a strong trend in favour of
levosimendan but was not statistically significant (OR
0.54 95% CI 0.25 to 1.17)). The levosimendan versus pla-
cebo group suggested a positive effect in favour of levosi-
mendan but did not achieve statistical significance (OR
0.66 (95% CI 0.11 to 4.08)) (Table 3).
Table 2 Risk of bias assessment of included studies
Source Adequate
sequence
generation
Allocation
concealment
Blinding Incomplete
outcome data
addressed
Free of
selective
reporting
Free of
other
Bias
Concurrent
therapies
similar
Overall
risk of
bias
Al-Shawaf
et al. [35]
Unclear Yes (sealed
envelopes)
No Unclear Yes Yes Yes Moderate
Alvarez et al.
[36]
unclear Unclear No Unclear Yes Yes Yes Moderate
Alvarez et al.
[37]
unclear Unclear No Unclear Yes Yes Yes Moderate
Barisin et al.
[38]
Yes (computer
generated)
Yes Yes (patients,
doctors,
adjudicators)
Unclear Yes Yes Yes Low
De Hert et al.
[39]
Yes (computer
generated)
Yes (sealed
envelopes)
Yes (adjudicators) Unclear Yes Yes Yes Low
De Hert et al.
[40]
Yes (computer
generated)
Yes (sealed
envelopes)
Yes(adjudicators) Unclear Yes Yes Yes Low
De Luca et al.
[41]
Unclear Unclear No Unclear Yes Yes Yes Moderate
Eriksson et al.
[42]
Yes (permutated
bocks)
Yes Yes (patients,
doctors)
Unclear Yes Yes Yes Low
Fuhrmann
et al. [33]
Yes (computer
generated)
Yes
(computer
generated)
Yes (patients
doctors)
Unclear Yes Yes Yes Low
Husedzinovic
et al. [43]
Yes (casting lots) Yes Yes (patients,
adjudicators)
Unclear Yes Yes Yes Moderate
Jarvela et al.
[44]
Yes (computer
generated)
Yes (sealed
envelopes)
Yes (patients,
doctors,
adjudicators)
Unclear Yes Yes Yes Low
Levin et al.
[45]
Yes (computer
generated)
Unclear No Unclear Yes Yes Yes Moderate
Lilleberg
et al. [46]
Unclear Unclear Yes (patients,
doctors,
adjudicators)
Unclear Yes Yes Yes Moderate
Samimi-Fard
et al. [47]
Unclear Unclear No Unclear Yes Yes Yes Moderate
Sonntag et al.
[48]
Unclear Yes Yes (patients,
doctors,
adjudicators)
Unclear Yes Yes Yes Moderate
Tritapepe
et al. [49]
Yes
(computer
generated)
Unclear Yes (Patients,
physicians,
adjudicators)
Unclear Yes Yes Yes Low
Tritapepe
et al.[ 1 ]
Yes (computer
generate)
Unclear Yes (patients,
physicians,
adjudicators)
Unclear Yes Yes Yes Low
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Page 5 of 10Figure 2 Forest plot for risk of mortality with subgroups elective and emergency revascularisation.
Figure 3 Forest plot for cardiac index with sub-groups dobutamine, placebo and phosphodiesterase inhibitors.
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Cardiogenic shock (CS) is a devastating complication of
ST-segment myocardial infarction (STEMI) and occurs
in 5 to 8% of these patients [12]. Thirty-day survival of
STEMI patients in cardiogenic shock is between 40%
and 60% [12,13]. Despite favourable trends in the last 30
years, survival to 6 years remains poor and may be as
low as 30% [14-16]. This is comparable to many forms
of cancer. Therapeutic options for haemodynamic sup-
port after coronary revascularisation are limited to phar-
macologic or mechanical interventions. Pharmacologic
choices are vasopressors and inotropic drugs. Inotropic
agents are essential to address the contractile dysfunc-
tion that occurs by providing short-term haemodynamic
improvement. However, this happens at a cost of
increased oxygen demand, arrythmogenesis and poten-
tial myocardial injury at a time when the myocardium is
most vulnerable. Data on comparison between inotropes
are scant and recent reports have highlighted the chal-
lenge in selecting the best pharmacologic option
[17-19]. Compared with norepinephrine, the use of
dopamine in patients with cardiogenic shock has been
associated with an increased rate of death [17].
A recent meta-analysis evaluated the use of levosimen-
dan in a variety of patient populations that included
post-cardiac surgery, post-vascular surgery, sepsis,
decompensated heart failure and post percutaneous cor-
onary intervention (PCI) patients [20]. The proposed
mechanisms of myocardial dysfunction in sepsis, after
non-cardiac surgery and in the context of cardiogenic
shock, are all quite disparate [21,22]. This implies that
vasoactive drugs may perform differently, depending on
the prevailing mechanism of shock making the interpre-
tation of a pooled analysis of such a heterogeneous
group of patients difficult. For this reason we limited
this meta-analysis to patients having coronary
revascularisation.
Overall, this study shows a mortality benefit when
levosimendan was used in patients having coronary
revascularisation. The effect was significant in the elec-
tive revascularisation group. The subset of patients
undergoing emergency revascularisation was under-
represented and the mortality benefit in this group was
not statistically significant. This latter analysis is prob-
ably underpowered. Additionally, levosimendan was
associated with favourable outcomes in several clinically
Figure 5 Forest plot comparing rates of post revascularisation atrial fibrillation for levosimendan versus control.
Figure 4 Forest plot of comparison of levosimendan vs control with Troponin I level as the outcome measure outcome.
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atrial fibrillation was reduced. Atrial fibrillation after
coronary revascularisation is associated with a prolonged
hospital stay, increased morbidity and long-term mortal-
ity [23]. The analysis also found levosimendan to be
associated with a reduction in peri-procedural cardiac
troponin I levels. Elevations in cardiac troponin I levels
are a valuable marker of myocardial damage after coron-
ary revascularisation and have been associated with a
significantly higher rate of in-hospital and long-term
mortality [24-27]. The haemodynamic response to levo-
simendan was also favourable. It is likely that the
improvement of haemodynamic profile observed with
levosimendan can be sustained for a longer period of
time compared to dobutamine or milrinone [28]. This is
because levosimendan has a poorly protein-bound active
metabolite and may exert clinical effects for up to a
week [29], at a much lower energy expenditure than
conventional inotropes.
The sub-group analysis comparing levosimendan to
the placebo, dobutamine and phoshodiesterase inhibitors
all showed a favourable trend towards levosimendan
with only the latter group showing statistical signifi-
cance. This observation could be interpreted as potential
harm from exposure to phosphodiesterase inhibitors.
Levosimendan reduced the ICU length of stay by a
mean of 26.18 hours (95% CI 46.20 to 6.16). The esti-
mated mean cost of critical care is US$3,518/day in the
United States and about £1,647/day in the United King-
dom [30,31]. Levosimendan is considerably more expen-
sive than conventional treatment and this probably
warrants further pharmaco-economic evaluation.
The findings of this meta-analysis must be viewed in
the context of other randomised studies and systematic
reviews comparing other vasoactive agents [17,29,32].
Thackray et al. systematically reviewed the use of ino-
tropes in cardiac failure [32].T h ed r u g si n c l u d e dw e r e
beta agonists, dobutamine, dopexamine and phospho-
diesterase inhibitors. Compared with the placebo, these
drugs were found to be associated with a non-significant
trend for increased rate of death (OR 1.5, 95% CI 0.51
to 3.92).
Our study has several limitations. Several studies were
of sub-optimal quality. Eight of the 17 studies included
did not have clear allocation concealment. This has the
potential to exaggerate treatment effects. Only five stu-
dies explicitly stated that the analysis was done by an
intention to treat principle. The study by Fuhrmann had
a small number of events(i.e. all cause mortality at 30
days) and was stopped early for patient benefit [33].
This study may potentially represent an exaggerated
effect size in favour of levosimendan [34]. The sensitivity
analysis considering the effect of levosimendan on mor-
tality across comparator drugs showed a more pro-
nounced effect compared with the phosphodiesterase
group. Comparing levosimendan to placebo is probably
of little value when suitable alternatives exist. These stu-
dies recruited low risk patients with a low event rate.
Lower event rates require larger sample sizes and it is
unsurprising that no statistically significant mortality
difference was demonstrated.
Publication bias may account for some of the effects
observed. Selective reporting of smaller studies, usually
of lower methodological quality will tend to exaggerate
treatment effects. The funnel plot was symmetrical, sug-
gesting a low probability of publication bias. Not all
Figure 7 Funnel Plot for risk of mortality including all studies.
Figure 6 Forest plot comparing length of stay in the levosimendan versus control groups.
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465 patients were included in the analysis of atrial fibril-
lation rates and only 470 patients were included in the
analysis of length of ICU stay.
Conclusions
This meta-analysis suggests that the use of levosimen-
dan in patients having coronary revascularisation is
associated with a significant reduction in mortality.
Additionally, the use of levosimendan is also associated
with improvement in haemodynamics and reduction in
cardiac biomarkers, length of ICU stay and rate of
atrial fibrillation. A suitably powered RCT is required
to confirm these findings. Additionally, the exact tim-
ing and dosing of levosimendan in patients undergoing
coronary revascularisation needs to be specifically
addressed.
Key messages
￿ Acute cardiovascular dysfunction after coronary
revascularisation occurs in about 8% to 25% of
patients.
￿ The short-term use of inotropes is crucial to
restoring haemodynamics and tissue perfusion
though the ideal inotrope in this group of patents is
controversial.
￿ Levosimendan has a potential role in reducing the
mortality and morbidity associated with coronary
revascularisation.
Additional material
Additional file 1: Search strategy for PUBMED.
Additional file 2: Risk of Bias Table (e Figure 1).
Abbreviations
CI: confidence interval; CS: cardiogenic shock; OR: odds ratio; PCI:
percutaneous coronary intervention; RR: relative risk; RCT: randomised
controlled trials; STEMI: ST-segment myocardial infarction.
Authors’ contributions
All of the authors contributed to the design of the study. RM and VM were
responsible for the statistical analysis. RM drafted the manuscript. All of the
authors critically revised the manuscript and agreed on the submitted
version.
Competing interests
The authors declare that they have no competing interests.
Received: 10 March 2011 Revised: 29 April 2011 Accepted: 8 June 2011
Published: 8 June 2011
References
1. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P,
Singer M: Levosimendan pre-treatment improves outcomes in patients
undergoing coronary artery bypass graft surgery. Br J Anaesth 2009,
102:198-204.
2. Lee CH, van Domburg RT, Hoye A, Lemos PA, Tanabe K, Smits PC, van der
Giessen WJ, de Feyter P, Serruys PW: Predictors of survival after
contemporary percutaneous coronary revascularization for acute
myocardial infarction in the real world. J Invasive Cardiol 2004, 16:627-631.
3. Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML,
White HD, Thompson TD, Topol EJ: Difference in countries’ use of
resources and clinical outcome for patients with cardiogenic shock after
myocardial infarction: results from the GUSTO trial. Lancet 1997,
349:75-78.
4. Pae WE Jr, Miller CA, Matthews Y, Pierce WS: Ventricular assist devices for
postcardiotomy cardiogenic shock. A combined registry experience. J
Thorac Cardiovasc Surg 1992, 104:541-552, discussion 552-543.
5. Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I,
De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M,
Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER,
Weder W, Follath F: Clinical review: practical recommendations on the
management of perioperative heart failure in cardiac surgery. Crit Care
14:201.
6. Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A: Comparison of
the hemodynamic effects of milrinone with dobutamine in patients
after cardiac surgery. J Cardiothorac Vasc Anesth 2001, 15:306-315.
7. Fowler MB, Alderman EL, Oesterle SN, Derby G, Daughters GT, Stinson EB,
Ingels NB, Mitchell RS, Miller DC: Dobutamine and dopamine after cardiac
surgery: greater augmentation of myocardial blood flow with
dobutamine. Circulation 1984, 70:I103-111.
8. Pagel PS: Levosimendan in cardiac surgery: a unique drug for the
treatment of perioperative left ventricular dysfunction or just another
inodilator searching for a clinical application? Anesth Analg 2007,
104:759-761.
9. MetaRegister of Controlled Clinical Trials. [http://www.controlled-trials.
com/mrct].
10. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ 2009, 339:b2535.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP,
Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ (Clin Res Educ)
2009, 339:b2700.
12. Reynolds HR, Hochman JS: Cardiogenic shock: current concepts and
improving outcomes. Circulation 2008, 117:686-697.
13. Dauerman HL, Goldberg RJ, White K, Gore JM, Sadiq I, Gurfinkel E, Budaj A,
Lopez de Sa E, Lopez-Sendon J, Global Registry of Acute Coronary Events.
GRACE Investigators: Revascularization, stenting, and outcomes of
patients with acute myocardial infarction complicated by cardiogenic
shock. Am J Cardiol 2002, 90:838-842.
14. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J,
White HD: Early revascularization and long-term survival in cardiogenic
Table 3 A sensitivity analysis
Number of studies OR 95% CI P for overall effect I
2 %
Studies with low risk of bias 8 0.25 0.09 to 0.68 0.007 0
Levosimendan versus placebo 9 0.66 0.11 to 4.08 0.65 35
Levosimendan versus phosphodiesterase 4 0.23 0.08 to 0.65 0.003 0
Levosimendan versus dobutamine 4 0.54 0.25 to 1.17 0.12 43
A sensitivity analysis including only studies with a low risk of bias, and comparing levosimendan to placebo, phosphodiesterase inhibitors and dobutamine.
OR, odds ratio; I
2, heterogeneity
Maharaj and Metaxa Critical Care 2011, 15:R140
http://ccforum.com/content/15/3/R140
Page 9 of 10shock complicating acute myocardial infarction. JAMA 2006,
295:2511-2515.
15. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM,
Holmes DR Jr: Long-term outcome and its predictors among patients
with ST-segment elevation myocardial infarction complicated by shock:
insights from the GUSTO-I trial. J Am Coll Cardiol 2007, 50:1752-1758.
16. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J: Thirty-year
trends (1975 to 2005) in the magnitude of, management of, and
hospital death rates associated with cardiogenic shock in patients with
acute myocardial infarction: a population-based perspective. Circulation
2009, 119:1211-1219.
17. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C,
Brasseur A, Defrance P, Gottignies P, Vincent JL: Comparison of dopamine
and norepinephrine in the treatment of shock. N Engl J Med 2010,
362:779-789.
18. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P,
Mebazaa A: Inotropes in cardiac patients: update 2011. Curr Opin Crit Care
2010, 16:432-441.
19. Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I,
De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M,
Poldermans D, Ranucci M, Karpati PC, Wouters P, Seeberger M, Schmid ER,
Weder W, Follath F: Clinical review: practical recommendations on the
management of perioperative heart failure in cardiac surgery. Crit Care
2010, 14:201.
20. Guarracino F, Landoni G, Baldassarri R, Nobile L, Stefani M: Concomitant
levosimendan and esmolol infusion in ischaemic cardiogenic shock. Br J
Anaesth 2010, 104:388-389.
21. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P: Experimental
models of sepsis and their clinical relevance. Shock 2008, 30(Suppl
1):53-59.
22. Hunter JD, Doddi M: Sepsis and the heart. Br J Anaesth 2010, 104:3-11.
23. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P,
Cantore C, Biglioli P, Sala A: Atrial fibrillation after isolated coronary
surgery affects late survival. Circulation 2008, 118:1612-1618.
24. Alcock RF, Roy P, Adorini K, Lau GT, Kritharides L, Lowe HC, Brieger DB,
Freedman SB: Incidence and determinants of myocardial infarction
following percutaneous coronary interventions according to the revised
Joint Task Force definition of troponin T elevation. Int J Cardiol 2010,
140:66-72.
25. Lurati Buse GA, Koller MT, Grapow M, Bolliger D, Seeberger M, Filipovic M:
The prognostic value of troponin release after adult cardiac surgery - a
meta-analysis. Eur J Cardiothorac Surg 2010, 37:399-406.
26. van Geene Y, van Swieten HA, Noyez L: Cardiac troponin I levels after
cardiac surgery as predictor for in-hospital mortality. Interact Cardiovasc
Thorac Surg 2010, 10:413-416.
27. Paparella D, Scrascia G, Paramythiotis A, Guida P, Magari V, Malvindi PG,
Favale S, de Luca Tupputi Schinosa L: Preoperative cardiac troponin I to
assess midterm risks of coronary bypass grafting operations in patients
with recent myocardial infarction. Ann Thorac Surg 2010, 89:696-702.
28. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z: The
effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized
preparations and phosphodiesterase enzymes of the guinea pig. Eur J
Pharmacol 2004, 486:67-74.
29. Toller WG, Stranz C: Levosimendan, a new inotropic and vasodilator
agent. Anesthesiology 2006, 104:556-569.
30. Halpern NA, Pastores SM: Critical care medicine in the United States
2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and
costs. Crit Care Med 2010, 38:65-71.
31. Hutchings A, Durand MA, Grieve R, Harrison D, Rowan K, Green J, Cairns J,
Black N: Evaluation of modernisation of adult critical care services in
England: time series and cost effectiveness analysis. BMJ 2009, 339:b4353.
32. Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and
relative effectiveness of intravenous inotropic drugs acting through the
adrenergic pathway in patients with heart failure-a meta-regression
analysis. Eur J Heart Fail 2002, 4:515-529.
33. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP,
Rauwolf T, Weinbrenner C, Strasser RH: Levosimendan is superior to
enoximone in refractory cardiogenic shock complicating acute
myocardial infarction. Crit Care Med 2008, 36:2257-2266.
34. Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D,
Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO,
Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz
Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H,
Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, et al: Stopping randomized
trials early for benefit and estimation of treatment effects: systematic
review and meta-regression analysis. JAMA 303:1180-1187.
35. Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R:
Levosimendan or milrinone in the type 2 diabetic patient with low
ejection fraction undergoing elective coronary artery surgery. J
Cardiothorac Vasc Anesth 2006, 20:353-357.
36. Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O,
Bascuas B, Perez-Paz J, Ginesta V: [Hemodynamic effects of levosimendan
following cardiac surgery]. Rev Esp Anestesiol Reanim 2005, 52:389-394.
37. Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J,
Ginesta V, Rubio J, Garcia-Bengoechea JB, Gonzalez-Juanatey JR:
[Hemodynamic effects of levosimendan compared with dobutamine in
patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol
2006, 59:338-345.
38. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D:
Levosimendan in off-pump coronary artery bypass: a four-times masked
controlled study. J Cardiovasc Pharmacol 2004, 44:703-708.
39. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ: The effects
of levosimendan in cardiac surgery patients with poor left ventricular
function. Anesth Analg 2007, 104:766-773.
40. De Hert SG, Lorsomradee S, vanden Eede H, Cromheecke S, Van der
Linden PJ: A randomized trial evaluating different modalities of
levosimendan administration in cardiac surgery patients with myocardial
dysfunction. J Cardiothorac Vasc Anesth 2008, 22:699-705.
41. De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A,
Sardella G, Genuini I, Fedele F: Levosimendan improves hemodynamics
and coronary flow reserve after percutaneous coronary intervention in
patients with acute myocardial infarction and left ventricular
dysfunction. Am Heart J 2005, 150:563-568.
42. Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, Leino KA,
Kuitunen AH, Kuttila KT, Peräkylä TK, Sarapohja T, Suojaranta-Ylinen RT,
Valtonen M, Salmenperä MT: Levosimendan facilitates weaning from
cardiopulmonary bypass in patients undergoing coronary artery bypass
grafting with impaired left ventricular function. Ann Thorac Surg 2009,
87:448-454.
43. Husedzinovic I, Barisin S, Bradic N, Barisin A, Sonicki Z, Milanovic R:
Levosimendan as a new strategy during off-pump coronary artery
bypass grafting: double-blind randomized placebo-controlled trial. Croat
Med J 2005, 46:950-956.
44. Jarvela K, Maaranen P, Sisto T, Ruokonen E: Levosimendan in aortic valve
surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth
2008, 22:693-698.
45. Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, Tanus E,
del Mazo CD: [The calcium sensitizer levosimendan gives superior results
to dobutamine in postoperative low cardiac output syndrome]. Rev Esp
Cardiol 2008, 61:471-479.
46. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L,
Verkkala K, Mattila S, Salmenpera M: Effects of a new calcium sensitizer,
levosimendan, on haemodynamics, coronary blood flow and myocardial
substrate utilization early after coronary artery bypass grafting. Eur Heart
J 1998, 19:660-668.
47. Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-
Gonzalez P: Effects of levosimendan versus dobutamine on long-term
survival of patients with cardiogenic shock after primary coronary
angioplasty. Int J Cardiol 2008, 127:284-287.
48. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX: The calcium sensitizer
levosimendan improves the function of stunned myocardium after
percutaneous transluminal coronary angioplasty in acute myocardial
ischemia. J Am Coll Cardiol 2004, 43:2177-2182.
49. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, Puddu PE,
Singer M, Pietropaoli P: Preconditioning effects of levosimendan in
coronary artery bypass grafting–a pilot study. Br J Anaesth 2006,
96:694-700.
doi:10.1186/cc10263
Cite this article as: Maharaj and Metaxa: Levosimendan and mortality
after coronary revascularisation: a meta-analysis of randomised
controlled trials. Critical Care 2011 15:R140.
Maharaj and Metaxa Critical Care 2011, 15:R140
http://ccforum.com/content/15/3/R140
Page 10 of 10